Merck & Co., Inc. (MRK) Gets Positive EU Opinion for ENFLONSIA Expansion

What happened

The EU Committee for Medicinal Products for Human Use recommended expanding Merck’s ENFLONSIA use to prevent RSV lower respiratory tract disease in children up to 24 months at increased risk through their second RSV season. The European Commission is expected to decide within two months.

Confirmed

Global impact / market context

If the European Commission approves the expansion, more children could become eligible for ENFLONSIA, potentially widening the medicine’s market and future sales opportunity. The recommendation is not final authorization, however, and the supplied context gives no sales estimate or expected financial impact.

Analyst inference

This is an early regulatory step, not a completed European launch expansion. The context says ENFLONSIA is already approved in more than 55 countries for infants during their first RSV season; the pending European decision and separate U.S. application could shape future access.

Confirmed

What to watch

1. The European Commission’s decision, expected within two months, will determine whether Merck can market ENFLONSIA in Europe for the expanded group of children. Confirmed
2. The separate U.S. application has a stated PDUFA target action date; the FDA’s decision will determine whether the application advances toward approval. Confirmed
3. If authorization expands, watch for evidence that eligible patient numbers translate into prescriptions and revenue; the supplied context provides no uptake or sales forecast. Analyst inference

Evidence

• Original source link unavailable